自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

  • <tfoot id="icskm"></tfoot>
  • <code id="icskm"><xmp id="icskm"></xmp></code>
  • <li id="icskm"><input id="icskm"></input></li>
    <code id="icskm"></code>
  • <cite id="icskm"><center id="icskm"></center></cite><button id="icskm"><bdo id="icskm"></bdo></button><code id="icskm"></code>
  • <cite id="icskm"><pre id="icskm"></pre></cite>
    <button id="icskm"></button>
  • <rt id="icskm"><pre id="icskm"></pre></rt>
    <cite id="icskm"></cite>
    <li id="icskm"></li>
    <button id="icskm"><input id="icskm"></input></button>
  • 159-2642-3062 027-65317797
    服務熱線(工作日:9:00-17:30)

    瀏覽量: 484

    • 產(chǎn)品名稱: DXD
    • 產(chǎn)品貨號: CS00056
    • 貨期: 現(xiàn)貨
    • 價格與訂購: 1390
    • 數(shù)量:
      庫存: 10
    • 規(guī)格: 1mg
    • 產(chǎn)品信息
    • 如何訂購
      產(chǎn)品描述
       Dxd is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC. 
      靶點活性
      Topoisomerase I    Camptothecins  
      體外活性
      Dxd shows obviously suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines with IC50s of 26.8, 25.4, and 6.7 ng/mL respectively, but with no such inhibition on MDA-MB-468 (IC50, >10,000 ng/mL)[1]. 
      體內活性
      Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM. In HER2 low-expressing ST565 and ST313 models has HER2 IHC 1+/FISH-negative expression[1].
      別名
      Exatecan derivative for ADC , 化合物Dxd
      純度
      98%
      分子量
      493.48 
      分子式
      C26H24FN3O6
      CAS No. 
      1599440-33-1
      存儲
      Powder: -20°C for 3 years
      In solvent: -80°C for 2 years
      溶解度
      DMSO: 50 mg/mL (101.32 mM)
      H2O: insoluble
      ( < 1 mg/ml refers to the product slightly soluble or insoluble )
      參考文獻
      1. Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.
      Note
      For research use only .
    黄骅市| 北京市| 平舆县| 龙游县| 雷波县| 嫩江县| 镇赉县| 舟山市| 广河县| 庄河市| 德令哈市| 屏边| 南华县| 灯塔市| 九寨沟县| 德惠市| 郎溪县| 桃源县| 格尔木市| 普洱| 佛冈县| 万宁市| 乐昌市| 苍南县| 兰坪| 阿尔山市| 灵丘县| 崇义县| 兴隆县| 临漳县| 贺兰县| 平南县| 白朗县| 芦山县| 义马市| 南平市| 灵寿县| 利津县| 台中县| 城口县| 安康市|